Limits...
The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study.

Al-Arouj M, Hassoun AA, Medlej R, Pathan MF, Shaltout I, Chawla MS, Hristoskova S, Ditommaso S, Kadwa MY - Int. J. Clin. Pract. (2013)

Bottom Line: A higher proportion of SU-treated patients experienced adverse events (AEs) compared with vildagliptin (22.8% vs. 10.2%).In this real-world study of fasting Muslim patients with T2DM, vildagliptin was associated with significantly fewer hypoglycaemic episodes compared with SU therapy.Vildagliptin was well tolerated in this patient population.

View Article: PubMed Central - PubMed

Affiliation: Dasman Diabetes Institute, Kuwait, Kuwait.

Show MeSH

Related in: MedlinePlus

Number of patients with hypoglycaemic events (HEs) during Ramadan fasting. Includes patients with a postbaseline assessment of HEs. *Fishers exact test
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4230330&req=5

fig01: Number of patients with hypoglycaemic events (HEs) during Ramadan fasting. Includes patients with a postbaseline assessment of HEs. *Fishers exact test

Mentions: For the primary study end-point, significantly fewer patients experienced ≥ 1 HE with vildagliptin (n = 36/669, 5.4%) compared with those receiving SUs (n = 123/621, 19.8%) [OR (95% CI) = 0.23 (0.156; 0.340), p < 0.001] (Figure 1A). No patients reported a grade 2 (severe) HE with vildagliptin compared with four patients receiving SUs (p = 0.053) (Figure 1B). The majority of patients experiencing hypoglycaemia during fasting reported a single HE [30 patients (4.5%) in the vildagliptin group and 109 patients (17.6%) in the SU group]. Overall, six patients (0.9%) experienced more than one HE in the vildagliptin group compared with 14 (2.3%) in the SU group.


The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study.

Al-Arouj M, Hassoun AA, Medlej R, Pathan MF, Shaltout I, Chawla MS, Hristoskova S, Ditommaso S, Kadwa MY - Int. J. Clin. Pract. (2013)

Number of patients with hypoglycaemic events (HEs) during Ramadan fasting. Includes patients with a postbaseline assessment of HEs. *Fishers exact test
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4230330&req=5

fig01: Number of patients with hypoglycaemic events (HEs) during Ramadan fasting. Includes patients with a postbaseline assessment of HEs. *Fishers exact test
Mentions: For the primary study end-point, significantly fewer patients experienced ≥ 1 HE with vildagliptin (n = 36/669, 5.4%) compared with those receiving SUs (n = 123/621, 19.8%) [OR (95% CI) = 0.23 (0.156; 0.340), p < 0.001] (Figure 1A). No patients reported a grade 2 (severe) HE with vildagliptin compared with four patients receiving SUs (p = 0.053) (Figure 1B). The majority of patients experiencing hypoglycaemia during fasting reported a single HE [30 patients (4.5%) in the vildagliptin group and 109 patients (17.6%) in the SU group]. Overall, six patients (0.9%) experienced more than one HE in the vildagliptin group compared with 14 (2.3%) in the SU group.

Bottom Line: A higher proportion of SU-treated patients experienced adverse events (AEs) compared with vildagliptin (22.8% vs. 10.2%).In this real-world study of fasting Muslim patients with T2DM, vildagliptin was associated with significantly fewer hypoglycaemic episodes compared with SU therapy.Vildagliptin was well tolerated in this patient population.

View Article: PubMed Central - PubMed

Affiliation: Dasman Diabetes Institute, Kuwait, Kuwait.

Show MeSH
Related in: MedlinePlus